Introduction
The microenvironment of colorectal cancer (CRC) cells can influence whether they will metastasise or remain dormant (Ribatti et al., 2006; Gout and Huot, 2008; Witz, 2009 ).
The presence of tumour infiltrating lymphocytes (TIL) within CRC may diminish metastasis formation, improving survival (Pages et al., 2010) . Interactions between CRC cells and TIL occur via trans-membrane proteins. For example, HLA-DR is required for tumour-associated antigen recognition by CD4 + T-cells. Increased HLA-DR expression on CRC cells can stimulate CD4 + T-helper cells and natural killer cells by presenting tumour-associated antigens resulting in interferon-γ production, and is an independent factor for better survival outcomes (Matsushita et al., 2006) . Surface antigens on CRC cells may interact with partner molecules on other cell types, affecting the phenotype of the cancer and cells within the microenvironment.
In recent years, proteomic analyses have been used to discover prognostic 'markers'
for CRC (Pei et al., 2007; Alfonso et al., 2008) . However, no single marker has improved the prognostic power of current clinico-pathological staging, or gained wide acceptance for use in routine pathology. A CD (cluster of differentiation) microarray containing 82 antibodies has been developed that provides extensive surface profiles of all the common leukemias, enabling their classification based solely on 'surface signatures' (Belov et al., 2006) . We have modified this microarray by addition of 40 antibodies against CRC surface proteins, identified from the literature. The 122-antibody DotScan™ CRC microarray consists of the 82-antibodies recognizing a range of lineage-specific leukocyte CD antigens that are adhesion molecules, receptors and markers of inflammation and immune response (Belov et al., 2006) , with a satellite array of 40 antibodies for CRC surface proteins. In this paper, profiles of surface proteins were determined on live CRC cells and TIL, isolated from disaggregated primary tumours. These profiles have been used to identify signatures on CRC
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4 and TIL that predict systemic relapse, i.e., distant metastasis and cancer-specific death in CRC patients (overall survival).
Materials and Methods

Samples from CRC resection specimens
Fresh CRC specimens were collected from 45 patients at the Royal Prince Alfred
Hospital (Camperdown, NSW, Australia) and Concord Repatriation General Hospital (Concord West, NSW, Australia) with informed consent under Protocol No. X08-164. Each CRC sample was macro-dissected from resected specimens that were verified as CRC by histopathology and staged and graded according to the Australian Clinico-Pathological (ACP)
Staging system for CRC (Davis and Newland, 1983) . The 4 main group stages of this system Tumour-Node-Metastasis (pTNM) system (Fielding et al., 1991) . Surface antigen profiles of Stages A, B, C and D tumours were subjected to statistical analysis. Normal mucosa was taken from the same patient sample at least 10 cm from the site of the tumour as a control.
Patients were monitored for systemic relapse and survival (median follow-up time 45 months) from the date of resection. Detailed patient information is listed in Table 1 . 
Surface profiling of CRC cells and TIL
Tissue disaggregation, cell fractionation, cell capture on DotScan™ CRC microarrays and fluorescence multiplexing with labeled antibodies were carried out as previously described (Zhou et al., 2010; Zhou et al., 2011 antibody.
Antigen analysis
Patient follow-up information (relapse and survival) was obtained for the 45 patients.
Antigens associated with metastasis were identified by Cox proportional hazards regression analysis from the 45 CRC surface profiles. Stage D patients were used to define metastatic potential and provide an accurate representation of the metastatic antigen profile. Stage A/B/C patients who subsequently developed systemic relapse may have had occult metastases at the time of operation not diagnosed but found subsequently during follow-up.
The analysis was repeated with 41 TIL surface profiles. Four of the TIL profiles were excluded as fluorescence multiplexing was unable to detect distinct profiles. Antigens associated with cancer-specific death were identified from the 45 CRC surface profiles by
Cox proportional hazards regression analysis. Patients who had succumbed to CRC-related death were included in the analysis while those who died from other causes were also included but had their survival times censored at date of death. The analysis was repeated with the 41 TIL surface profiles. Systemic relapse is defined as the spread of CRC to distant sites (e.g., liver, lungs) and cancer-specific death as the cause of death being directly
attributed to CRC. Survival times for other patients were censored at the date of their last follow-up visit.
Clustering selected antigens in relation to outcomes
Antigens that were significantly associated with systemic metastases and/or survival (log rank p≤0.05) were selected for unsupervised hierarchical clustering (Average linkage,
Pearson correlation) using MeV software. Predictive systemic relapse and survival signatures were identified based on the CRC antigen clusters. This analysis was repeated for the TIL antigens.
Relating surface signatures to outcomes
Surface signatures were identified that correlated with systemic relapse and cancerspecific death. Patients with existing metastasis (Stage D) were not considered to be in systemic relapse and were excluded from analysis of the relapse signatures. Kaplan-Meier curves were constructed using CRC systemic relapse and survival signatures, the curves were compared using the log-rank test. This analysis was repeated with the TIL signatures. To determine the independence of our signatures from clinico-pathologic variables in predicting a patient's risk of systemic relapse or cancer-specific death, we analyzed the signatures, together with available clinical variables, using multivariate Cox proportional hazard models.
The proportional hazards assumption was evaluated graphically. Other clinical variables considered as potential predictors of outcome were gender, age (<68 or ≥68), tumour spread beyond the muscularis propria, lymph-node infiltration, presence of distant metastases, and neutrophil to lymphocyte ratios (NLR). Variables were considered significant if the Wald's test p-value was <0.05 (unadjusted p-value < 0.05 considered significant). Data were analyzed with the SPSS statistical package version 21.0 (SPSS, Chicago, IL, USA). No patients developed loco-regional relapse. All surviving patients were followed-up for at least 3 years after resection (median 45 months). During this period there were 13 deaths, of which 9 were cancer-specific, including 3 patients who were noted to have incurable CRC at the time of surgery.
A C C E P T E D
Antigen analysis
Analyses of the 45 CRC and 41 TIL surface profiles identified 11 CRC and 11 TIL antigens that were significantly associated with metastasis (inclusive of patients with existing
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9 metastasis and systemic relapse) and/or cancer-specific survival, respectively (Table 2) . A subset of differentially abundant antigens retained significance when modeled together with a known prognostic factor, the presence/absence of lymph node infiltration, using multivariate Cox regression analysis (Supplementary Table S1 ). The unique sets of antigens found on CRC and TIL correlate well with previously published information on CRC development and progression as well as T-cell immunity (summarized in Table 2 ). 
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↑ CD181
Poor survival Expressed on a sub-set of NK-like T-cells. CD181 + T-cells have limited CRC tumour infiltration potential due to the absence of CD26 (trans-endothelial migration) and MadCAM-1 (gut homing) (Qin et al., 1996) .
↑ Galectin-4
Poor survival Secreted by CRC cells to bind to activated T-cells at the CD3 region, which is translated into a potent inhibition of cell cycle progression and induction of antigen-induced cell death (Paclik et al., 2008) ↑ CA19-9 Poor survival Sialylated Lewis a blood group antigen, secreted in high concentrations into serum of patients with CRC (Yamada et al., 1995) ↑ TSP-1 Poor survival Role in the recruitment, activation and retention of infiltrating T-cells in the lesions of inflammatory diseases.
Facilitates adhesion and movement of T-cells into the tissue (Vallejo et al., 2000) The CD antigens listed were found by us to be significantly (p≤0.05) associated with metastasis and/or cancer-specific survival by univariate Cox regression analysis (antigen expression was used as a continuous variable) Abbreviations: CA-125 (cancer antigen 125); CA19-9 (carbohydrate antigen 19-9); EGFR (epidermal growth factor receptor); TSP-1 (thrombospondin 1)
Clustering of differentially abundant antigens and patient outcomes
Each set of 11 prognostic antigens (CRC and TIL) was subjected to hierarchical clustering and the patient groups were correlated with systemic relapse (metastasis) or cancer-specific death (overall survival). Figure 1 shows hierarchical clustering of the 45 CRC profiles and Figure 2 shows the clustering of the 41 TIL profiles. For the CRC and TIL profiles, patients clustered into two large groups representing relapse-free and systemic relapse. As anticipated, the systemic relapse group contained a sub-cluster that consisted predominantly of patients with cancer-related death. Using cluster membership as the exploratory variable, Kaplan-Meier curves indicate a difference in systemic relapse or survival times between the signatures (Figure 3 ; log-rank p = 0.002 and p <0.0001, respectively). These cluster memberships were then used to denote systemic relapse and cancer-specific death signatures. Similarly, systemic relapse and cancer-specific death signatures were identified from TIL profiles (log-rank test, p = 0.002 and p = 0.003, respectively). showing probability of cancer-specific survival after surgical resection (9 events); C) TIL signature showing probability of patients remaining free of systemic relapse after surgical resection of primary tumour (11 events); D) TIL signature showing probability of cancerspecific survival after surgical resection of primary tumour (8 events). p-values were calculated using the log-rank test.
Relating predictive signatures to outcomes
Multivariate Cox proportional hazard regression analysis was conducted with our CRC signatures and currently known predictors of CRC. The prognostic signatures were correlated with systemic relapse (4 stage D patients with pre-existing distant spread of CRC were excluded from the analysis) and cancer-specific survival. In Table 3 , the CRC survival signature correlated with patient survival (univariate analysis, p = 0.007) and retained significance with lymphatic invasion (multivariate analysis, p = 0.005). In Table 4 , TIL signatures for both relapse and survival correlated with patient systemic relapse (univariate analysis, p = 0.016) and survival (univariate analysis, p = 0.020), and retained significance with lymphatic invasion (multivariate analysis; relapse, p = 0.048; survival, p = 0.024).
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Discussion
The metastatic potential of primary CRC cells is a major determinant of disease progression and survival outcomes and is controlled in part by interactions within the tumour microenvironment, including the density and type of TIL. Recent data suggest that diseasefree and overall survival times are influenced by the local adaptive immune response (Pages et al., 2010) . Levels of surface antigens on CRC cells and TIL indicate some aspects of cell behavior and interactions that may govern disease progression (Gout and Huot, 2008) .
In this study, we have quantified surface antigens on live CRC cells and TIL from surgical specimens, and identified signatures associated with systemic relapse and cancerspecific death in CRC patients. The DotScan™ CRC microarray identified 11 antigens from CRC profiles associated with metastasis and diminished survival. Similarly, 11 antigens from TIL were associated with metastasis and/or survival. Hierarchical cluster analysis of the 11 CRC and TIL antigens produced similar groups of patients that were separated into three categories (relapse-free, systemic relapse, and cancer-specific death), supporting the hypothesis that surface antigen profiles on CRC cells and TIL yield prognostic information. (Wagner et al., 2001; Shelley et al., 2002; Lee et al., 2010) .
The lower concordances for TIL clusters compared with CRC clusters of patients that were relapse-free (58.9%) or succumbed to cancer-specific death (56.3%) show that there are no differential effects on TIL for patients in these categories. However, the CRC signatures for the 3 patient clusters corresponding to relapse-free, systemic relapse or cancer-specific death may have prognostic utility. Such profiling of CRC cells should be validated in a larger independent cohort of patients, perhaps in conjunction with a clinical trial.
The absence of an immune response within CRC has been linked to early metastatic spread (Pages et al., 2005) . In this study, pathological evidence indicated that 33% of CRC with a systemic relapse signature had medium to high levels of inflammatory leukocyte infiltration compared to 50% of tumours in the relapse-free category. Significant variations
were observed between surface antigen levels on T-cells in the systemic relapse-and relapsefree groups. In addition to reduced expression of activation markers, T-cells associated with relapse had limited tumour infiltration, as indicated by a reduction in the infiltration promoting antigens, CD31 and CD181 (Tanaka et al., 1992; Qin et al., 1996) . The inability of T-cells to infiltrate a tumour may prevent them from becoming stimulated and generating an anti-cancer response. An absence of TIL may enable metastatic invasion, as CRC cells transition to a more invasive, metastatic mesenchymal phenotype (Gout and Huot, 2008) . We detected evidence of epithelial to mesenchymal transitioning indicated by the replacement of the epithelial adhesion marker, CD49d (Stallmach et al., 1992) , with the endothelial adhesion and migration antigens, CD24, CA19-9 and Galectin-4 (Yamada et al., 1995; Nagy et al., 2003; Sagiv et al., 2006) on CRC cells in the systemic relapse group.
There is a discrepancy between the number of CRC samples with clinic-pathological positive can develop resistance to TSP-1 by secreting increased amounts of angiogenic factors that counter-balance the inhibitory effects of TSP-1 (Filleur et al., 2001) . Elevated serum CA19-9
is associated with relapse and poor survival in CRC patients (Wang et al., 2002) . CA19-9
(sialyl-Lewis a) epitopes are carried by serum MUC1 mucins secreted from CRC tumours (Zhang et al., 1996) . MUC1 reduces interaction and sensitivity to killing by T-cells, and may reduce T-cell interactions with tumour-associated ligands, protecting against immune surveillance (McDermott et al., 2001) .
In this paper, prognostic surface antigen signatures on CRC cells and TIL were identified from a group of CRC patients. The DotScan™ CRC microarray provides a rapid approach (workflow 3 h) for surface profiling of cells isolated from clinical samples. The size of the DotScan microarray could be reduced while retaining signature antibodies to reduce costs for large-scale clinical screening. While the results obtained are promising, validation in a larger independent patient cohort is required to confirm the surface signatures. The specificity of the signatures is low, this could be due to the relatively short follow-up period of 3 years. A longer period, e.g., 5 years, may provide a more accurate assessment of cancerfree survival with respect to specificity. There may be some bias in the results presented here as, due to the relatively small sample size, no validation could be performed. DotScan surface profiling of patient samples must be done with live cells, and patient outcome data takes time to collect.
To our knowledge, this study is the first to utilize concurrent surface antigen profiles from CRC cells and TIL isolated from surgical CRC samples to predict metastatic spread and 
